XML 66 R56.htm IDEA: XBRL DOCUMENT
v3.22.1

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - USD ($) $ in Millions | Apr. 30, 2022 | Jan. 31, 2022 | Oct. 31, 2021 | Apr. 30, 2021 | Jan. 31, 2021 | Oct. 31, 2020
--- | --- | --- | --- | --- | --- | ---
Assets |  |  |  |  |  |
Short term investments (Equity securities with RDFV) | $ 21 |  | $ 91 |  |  |
Liabilities |  |  |  |  |  |
Contingent Consideration | 67 | $ 92 | 89 | $ 96 | $ 0 | $ 0
Fair Value, Measurements, Recurring |  |  |  |  |  |
Assets |  |  |  |  |  |
Total assets measured at fair value | 692 |  | 1,084 |  |  |
Liabilities |  |  |  |  |  |
Total liabilities measured at fair value | 114 |  | 128 |  |  |
Fair Value, Measurements, Recurring | Other Current Assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Cash equivalents (money market funds) | 571 |  | 919 |  |  |
Derivative instruments (foreign exchange contracts) | 38 |  | 9 |  |  |
Short term investments (Equity securities with RDFV) | 21 |  | 91 |  |  |
Fair Value, Measurements, Recurring | Other assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Trading securities | 35 |  | 34 |  |  |
Other investments | 27 |  | 31 |  |  |
Fair Value, Measurements, Recurring | Other accrued liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Derivative instruments (foreign exchange contracts) | 12 |  | 5 |  |  |
Contingent Consideration | 64 |  | 62 |  |  |
Fair Value, Measurements, Recurring | Other long-term liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Deferred compensation liability | 35 |  | 34 |  |  |
Contingent Consideration | 3 |  | 27 |  |  |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) |  |  |  |  |  |
Assets |  |  |  |  |  |
Total assets measured at fair value | 622 |  | 1,036 |  |  |
Liabilities |  |  |  |  |  |
Total liabilities measured at fair value | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other Current Assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Cash equivalents (money market funds) | 571 |  | 919 |  |  |
Derivative instruments (foreign exchange contracts) | 0 |  | 0 |  |  |
Short term investments (Equity securities with RDFV) | 16 |  | 83 |  |  |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Trading securities | 35 |  | 34 |  |  |
Other investments | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other accrued liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Derivative instruments (foreign exchange contracts) | 0 |  | 0 |  |  |
Contingent Consideration | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Other long-term liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Deferred compensation liability | 0 |  | 0 |  |  |
Contingent Consideration | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) |  |  |  |  |  |
Assets |  |  |  |  |  |
Total assets measured at fair value | 70 |  | 48 |  |  |
Liabilities |  |  |  |  |  |
Total liabilities measured at fair value | 47 |  | 39 |  |  |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other Current Assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Cash equivalents (money market funds) | 0 |  | 0 |  |  |
Derivative instruments (foreign exchange contracts) | 38 |  | 9 |  |  |
Short term investments (Equity securities with RDFV) | 5 |  | 8 |  |  |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Trading securities | 0 |  | 0 |  |  |
Other investments | 27 |  | 31 |  |  |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other accrued liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Derivative instruments (foreign exchange contracts) | 12 |  | 5 |  |  |
Contingent Consideration | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Other long-term liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Deferred compensation liability | 35 |  | 34 |  |  |
Contingent Consideration | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) |  |  |  |  |  |
Assets |  |  |  |  |  |
Total assets measured at fair value | 0 |  | 0 |  |  |
Liabilities |  |  |  |  |  |
Total liabilities measured at fair value | 67 |  | 89 |  |  |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other Current Assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Cash equivalents (money market funds) | 0 |  | 0 |  |  |
Derivative instruments (foreign exchange contracts) | 0 |  | 0 |  |  |
Short term investments (Equity securities with RDFV) | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other assets |  |  |  |  |  |
Assets |  |  |  |  |  |
Trading securities | 0 |  | 0 |  |  |
Other investments | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Derivative instruments (foreign exchange contracts) | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other accrued liabilities | Resolution Bioscience, Inc. |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Contingent Consideration | 64 |  | 62 |  |  |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Deferred compensation liability | 0 |  | 0 |  |  |
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Other long-term liabilities | Resolution Bioscience, Inc. |  |  |  |  |  |
Liabilities |  |  |  |  |  |
Contingent Consideration | $ 3 |  | $ 27 |  |  |

X
- References No definition available. + Details
Name: | us-gaap_AssetsCurrentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_AssetsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + References No definition available. + Details
Name: | us-gaap_CashAndCashEquivalentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer). + References No definition available. + Details
Name: | us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps. + References No definition available. + Details
Name: | us-gaap_ForeignCurrencyContractAssetFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into. + References No definition available. + Details
Name: | us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_InvestmentsFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_LiabilitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of financial and nonfinancial obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258 + Details
Name: | us-gaap_LiabilitiesFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.4) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 + Details
Name: | us-gaap_TradingSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=a_ResolutionBioscienceIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |